- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Aquestive Therapeutics Inc (AQST)
Aquestive Therapeutics Inc stock price live, this page displays NASDAQ AQST stock exchange data. View the AQST premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Aquestive Therapeutics Inc real time stock price chart below.
What Is the Aquestive Therapeutics Inc Stock Price Today?
The Aquestive Therapeutics Inc stock price today is 3.930.
What Is the Stock Symbol for Aquestive Therapeutics Inc?
The stock symbol for Aquestive Therapeutics Inc is ""AQST.""
What Stock Exchange Does Aquestive Therapeutics Inc Trade On?
Aquestive Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Aquestive Therapeutics Inc a Good Stock to Buy?
Determining whether Aquestive Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AQST quote. (ISIN: US03843E1047)
What Is the Aquestive Therapeutics Inc Stock Price Today?
The Aquestive Therapeutics Inc stock price today is 3.930.
What Is the Stock Symbol for Aquestive Therapeutics Inc?
The stock symbol for Aquestive Therapeutics Inc is ""AQST.""
What Stock Exchange Does Aquestive Therapeutics Inc Trade On?
Aquestive Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Aquestive Therapeutics Inc a Good Stock to Buy?
Determining whether Aquestive Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AQST quote. (ISIN: US03843E1047)
3.930
-0.060(-1.50%)
Closed·
After Hours
3.921-0.009(-0.24%)
·
Fair Value
An estimate of a Aquestive Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.850
4.030
52 wk Range
2.120
5.800
AQST Scorecard
Full Analysis
Analysts anticipate sales decline in the current year
Earnings results expected in 3 days
1/2
Fair Value
An estimate of a Aquestive Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.8504.030
52 wk Range
2.1205.800
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AQST Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Aquestive Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
8.417
Upside
+114.16%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Aquestive Therapeutics Inc Company Profile
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Aquestive Therapeutics Inc SWOT Analysis
Innovative Delivery | Explore Aquestive's PharmFilm technology, revolutionizing drug administration through buccal, sublingual, and lingual delivery methods |
Anaphylm's Potential | Delve into Anaphylm, a groundbreaking sublingual epinephrine film poised to disrupt the anaphylaxis treatment market |
Market Dynamics | Analyst price targets range from $9 to $17, reflecting optimism about Anaphylm's market potential and Aquestive's growth prospects |
Competitive Edge | Learn how Aquestive's unique oral administration route for epinephrine could provide a significant advantage in patient compliance and market penetration |
Aquestive Therapeutics Inc Earnings Call Summary for Q1/2025
- Q1 2025 EPS of -$0.24 missed forecast, revenue fell to $8.7M; stock dropped 7.02% in premarket trading
- Net loss increased to $22.9M from $12.8M YoY; company revised 2025 revenue guidance down to $44-$50M
- Focus remains on ANNAFILM product with FDA review ongoing; potential commercial launch in early 2026
- CEO emphasized ANNAFILM as first oral medication for severe allergic reactions; exploring international partnerships
- Analysts revised earnings expectations downward; company faces regulatory hurdles and financial strain
Last Updated: 13/05/2025, 14:14
Read Full TranscriptCompare AQST to Peers and Sector
Metrics to compare | AQST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAQSTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.2x | 5.3x | −0.5x | |
PEG Ratio | 0.21 | 0.18 | 0.00 | |
Price/Book | −6.4x | −1.4x | 2.6x | |
Price / LTM Sales | 7.2x | 0.8x | 3.3x | |
Upside (Analyst Target) | 100.5% | 40.4% | 43.4% | |
Fair Value Upside | Unlock | 38.9% | 7.1% | Unlock |
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.417
(+114.16% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.24 / -0.16
Revenue / Forecast
8.70M / 12.23M
People Also Watch
FAQ
What Stock Exchange Does Aquestive Therapeutics Trade On?
Aquestive Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Aquestive Therapeutics?
The stock symbol for Aquestive Therapeutics is "AQST."
What Is the Aquestive Therapeutics Market Cap?
As of today, Aquestive Therapeutics market cap is 390.36M.
What Is Aquestive Therapeutics's Earnings Per Share (TTM)?
The Aquestive Therapeutics EPS (TTM) is -0.59.
When Is the Next Aquestive Therapeutics Earnings Date?
Aquestive Therapeutics will release its next earnings report on 10 Aug 2025.
From a Technical Analysis Perspective, Is AQST a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Aquestive Therapeutics Stock Split?
Aquestive Therapeutics has split 0 times.
How Many Employees Does Aquestive Therapeutics Have?
Aquestive Therapeutics has 142 employees.
What is the current trading status of Aquestive Therapeutics (AQST)?
As of 08 Aug 2025, Aquestive Therapeutics (AQST) is trading at a price of 3.93, with a previous close of 3.93. The stock has fluctuated within a day range of 3.85 to 4.03, while its 52-week range spans from 2.12 to 5.80.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.